The new Chinese Pharmacopoeia will be implemented on October 1 this year

It was learned from the State Food and Drug Administration that the 2010 edition of the "People's Republic of China Pharmacopoeia" (hereinafter referred to as the Chinese Pharmacopoeia) has been promulgated by the Ministry of Health in Announcement No. 5 of 2010 and will be implemented as of October 1, 2010. The State Food and Drug Administration website published an announcement on the implementation of matters on the 28th.

The announcement pointed out that all varieties included in the Chinese Pharmacopoeia, as of the date of implementation, were originally included in the historical version of the Pharmacopoeia, the Ministry of Health promulgated the drug standard, and the State Food and Drug Administration promulgated the new drug positive standard and the local standard of the same species Drug standards are also abolished.

The drug registration standards do not meet the requirements of the Chinese drug D8 and the procedural change drug label and label. The drugs produced on October 1st, 2010 must use changed specifications and labels. 2. 岜曜 惺 惺 惺 惺 氐 煅 煅 钅慷嘤谥 蛑 蛑 蛑 蛑 蛑 蛑 蛑 旮哂谥湟蟮 谥 谥 谥 兄 兄 敝 敝 敝 敝 敝 敝 敝 敝 敝 敝 敝 钅亢 钅亢 钅亢 钅亢 钅亢 钅亢 钅亢 钅亢 钅亢 钅亢 钅亢 钅亢 钅亢 钅亢. BR> The specifications of formulations not included in the Chinese Pharmacopoeia species are subject to the relevant requirements of the Chinese Pharmacopoeia and the specifications. The specifications are to be implemented according to the original approval documents. ?

The announcement emphasized that drug manufacturers should change the drug label and label according to the relevant provisions and procedures of the State Food and Drug Administration according to the revised contents of the Chinese Pharmacopoeia. Drugs produced from October 1, 2010 must use changed specifications and labels. For drugs whose common names have been revised, their original names can be used as transitions of previous names.

It is understood that the Chinese Pharmacopoeia includes general examples, texts, and appendices and is the statutory basis for drug development, production, operation, use, and supervision and management. All national drug standards should comply with the relevant requirements of the Chinese Pharmacopoeia and Appendix.